NEW

Activ Surgical Announces FDA Clearance for ActivSight Intraoperative Imaging Module

Activ Surgical announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ActivSight Intraoperative Imaging Module for enhanced surgical visualization.

Metrex Surface Disinfectant Portfolio Secures EPA Approval

The U.S. Environmental Protection Agency (EPA) has approved all eight surface disinfectant products made by an infection prevention leader, Metrex, as effective against SARS-CoV-2, the novel coronavirus that causes COVID-19.

Olympus Supports Safety Actions Regarding Surgical Smoke

Olympus has announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for health care staff in operating rooms.

Exofin Fusion Redesign Receives FDA Approval

Chemence Medical, a leader in medical cyanoacrylate devices and products, announced the U.S. Federal Drug Administration’s (FDA) 510(k) approval of the company’s redesigned exofin fusion skin closure system.

Diversey Acquires AHP Intellectual Property from Virox Technologies Inc.

Diversey Inc. has announced the acquisition of the global intellectual property rights related to Accelerated Hydrogen Peroxide (AHP), an innovative and revolutionary technology, from Virox Technologies, Inc.

Accelerated Hydrogen Peroxide (AHP) is a globally patented, synergistic blend of commonly used ingredients that produces exceptional potency as a germicide and superior performance as a cleaner. AHP has proven to be a fast, effective, responsible and sustainable solution.

Each year, healthcare-associated infections (HAIs) and food-borne illnesses impact millions of people globally. Over the past decade, Diversey and Virox have partnered to develop a number of AHP-based solutions to address these concerns, including leading brands such as Oxivir, Accel, and Viper.

In the last several years, Diversey has invested significantly to build a leadership position in healthcare and infection prevention through thought leadership, innovation, and evidence-based product and practice development. This acquisition supports Diversey’s continued mission to reduce preventable infections, control associated costs, and ultimately help save lives across world.

“With a mission to protect and care for people every day, infection prevention is a major focus for Diversey. Adding this intellectual property to our portfolio will enhance our ability to accelerate innovation and grow our position in infection prevention globally,” said Mark Burgess, CEO of Diversey, “It will inform our future investment decisions as we continue to apply science to protect people every day. This major acquisition reaffirms Diversey’s global commitment to achieve profitable growth through innovation and acquisition.”

Diversey will continue to license this technology to key partners where this innovative solution can be used to deliver value across other markets.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X